Concurrence of nivolumab‐induced interstitial lung disease and cancer invasion

Nivolumab improves overall survival rates of patients with advanced or recurrent non‐small‐cell lung cancer (NSCLC). Among immune‐related adverse events caused by nivolumab, interstitial lung disease (ILD) is a clinically serious and potentially life‐threatening toxicity, for which appropriate treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanai, Osamu, Nakatani, Koichi, Fujita, Kohei, Okamura, Misato, Mio, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553297/
https://www.ncbi.nlm.nih.gov/pubmed/28811904
http://dx.doi.org/10.1002/rcr2.257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553297/
https://www.ncbi.nlm.nih.gov/pubmed/28811904
http://dx.doi.org/10.1002/rcr2.257

Ejemplares similares